On Monday's trading session, major pharmaceutical companies Gland Pharma Ltd, Sun Pharmaceutical Industries Ltd, and Laurus Labs Ltd saw their shares reach new 52-week high levels. This surge occurred despite a general downward trend in domestic benchmarks, highlighting the sector's robust performance.
Gland Pharma recorded a significant jump of 15.85 percent, closing at Rs 2,164.40. Sun Pharmaceutical climbed 1 percent to Rs 1,896.90, while Laurus Labs moved up 0.63 percent to Rs 1,332.
Gland Pharma's Strong Q4 Performance
According to Elara Securities, Gland Pharma's Q4 FY26 results exceeded expectations. Revenue aligned with estimates, but better margins led to a 16 percent beat on EBITDA and a 32 percent beat on PAT, bolstered by higher other income. The company has shown consistent growth momentum after a period of lackluster performance, particularly benefiting from new complex product launches and contracts in regulated markets. Elara Securities maintained a 'Buy' rating for Gland Pharma, raising its target price to Rs 2,306.
Sun Pharmaceutical's Strategic Acquisition
Sun Pharmaceutical's shares rose following its definitive agreement to acquire Organon & Co in an all-cash transaction valued at $11.75 billion. HDFC Securities noted that this acquisition is expected to significantly scale up Sun Pharma's operations, provide growth revival in established brands, and cross-leverage its branded generic business. The deal, anticipated to close in early CY27, is projected to be sales, EBITDA, and PAT accretive by FY28, despite a temporary dilution in gross margin. HDFC Securities maintained a 'BUY' rating with a rolled-forward target price of Rs 2,030.
Laurus Labs Transitions to CDMO-Led Model
Laurus Labs is strategically shifting towards a Contract Development and Manufacturing Organization (CDMO)-led model, aiming for CDMO to contribute approximately 50 percent of its revenue by FY29E. Choice Institutional Equities highlighted expected growth across segments, including generics, supported by ARV recovery and oncology API scale-up. The evolving product mix, with a higher CDMO contribution, is anticipated to support margin expansion. Despite an expected slower growth in profitability due to elevated capital expenditure, Choice Institutional Equities maintained an 'Add' rating with a revised target price of Rs 1,255.
Positive Outlook for the Pharmaceutical Sector
Industry experts remain optimistic about the pharmaceutical sector. VK Vijayakumar, Chief Investment Strategist at Geojit Investments, emphasized the resilience of export-oriented sectors like pharmaceuticals. Siddhartha Khemka, Head of Research, Wealth Management, Motilal Oswal Financial Services Ltd (MOFSL), added that pharmaceutical stocks are likely to remain in focus due to persistent rupee weakness, improving export competitiveness, and sustained domestic healthcare demand. The sector's defensive earnings profile is also seen as a benefit amidst global macro uncertainty and market volatility.
Other pharmaceutical stocks, including Divi's Laboratories Ltd, Wockhardt Ltd, Torrent Pharmaceuticals Ltd, IPCA Laboratories Ltd, Glenmark Pharmaceuticals, and Ajanta Pharma, also experienced gains on Monday.